What this ETF is trying to do

The KRANESHARES MSCI ALL CHINA HEALTH CARE INDEX ETF (KURE) focuses on the healthcare industry in China. It holds a variety of companies involved in medicine and health services. As of October 7, 2026, some of its top holdings include Beone Medicines Ltd (8.93%), Innovent Biologics Inc (8.9%), and WuXi Biologics (Cayman) Inc (7.59%).

What the numbers show

The current price of the ETF is $18.72. To understand how the price has changed, we can look at the price return (which tracks only the share price) and the total return (which includes distributions).

• Year-to-Date: The price return and total return are both 9.86%.

• One Year: The price return was -9.39%, while the total return was -5.73%.

• Three Year: The price return was 4.76%, and the total return was 11.09%.

• Five Year: The total return was -38.01%.

For a simple example, if you had invested $10,000 based on the estimated price from roughly one year ago ($20.66), the price-only decline of -9.39% would mean your investment's share value would be approximately $9,061.

Income and distribution explanation

This ETF pays out cash to investors, known as distributions. It has a distribution yield of approximately 3.82%. However, these payments are irregular and less frequent; in the last 12 months, there was only one payout.

It is important for beginners to remember that a high distribution yield alone can be misleading. While these payments provide cash, they do not guarantee that the original money invested (the principal) will stay the same or grow.

NAV erosion explanation

"NAV erosion" happens when the value of the assets inside an ETF declines over time. StockValueFinder uses an erosion-risk score to measure this. KURE has an erosion score of 75, which is labeled as "mild price erosion." This is a measurement of risk rather than proof that the fund's value has collapsed.

Pros

• Positive year-to-date price and total returns.

• The three-year total return (11.09%) is higher than the three-year price return.

Cons

• The five-year total return shows a significant decline of -38.01%.

• The one-year price return is negative.

• Distributions are irregular.

Beginner takeaway

KURE gives investors exposure to Chinese healthcare companies. While it has seen some recent growth this year, its long-term five-year total return is negative. Investors often look for principal stability, meaning they want their initial investment to keep its value even while receiving income. In this case, the mild erosion-risk score and past price declines are important factors to notice.